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1. Introduction 
A wealth of information on brain metabolism has been gathered from studies in which 13C-
labeled metabolic substrates (often glucose) have been administered to human subjects or 
experimental animals. 13C Magnetic resonance spectroscopy (MRS1) of the brain (or extracts 
of brain) has shown to what degree the 13C-labeled compound has been metabolized, and, to 
some extent, along which metabolic pathways. The latter interpretation derives from the fact 
that 13C MRS shows the 13C labeling not of individual compounds, e.g. amino acids, but of 
individual carbon positions in those different compounds (Fig. 1). Because some enzymes of 
amino acid metabolism have a cell-specific expression, it is possible to study the metabolic 
activity of individual cell types or the transfer of amino acids between them. Finally, 13C 
MRS allows studies of a host of substrates to examine their potential as metabolic substrates 
for the brain. An extensive review, which included an overview of technical aspects of 13C 
MRS in studies of brain and cultured brain cells, appeared recently (Rodrigues et al., 2009). 
2. 
13
C MRS for the visualization of brain energy metabolism 
Glucose is considered the physiologic energy substrate of the brain and is used by all brain 
cells, neurons and glial cells alike. Glucose consumption is tightly coupled to the need for 
energy (ATP), which in the brain largely reflects neuronal activity, or more specifically, 
depolarization of neuronal cell membranes. The membrane potential derives from the ionic 
gradients created by ion pumps that transport sodium and potassium against their 
concentration gradients across cell membranes, an activity that is fuelled by ATP (Attwell 
and Laughlin, 2001). Therefore, alterations in neuronal activity will be reflected in changes 
in glucose consumption, and, conversely, constraints in the availability of glucose and 
oxygen will limit neuronal activity. 13C MRS after administration of 13C-labeled glucose to 
                                                 
1 Abbreviations:ATP: adenosine triphosphate, CoA: coenzyme A, GABA: -aminobutyrate, i.v. 
intravenously, MRS: magnetic resonance spectroscopy, PET; positron emission tomography, TCA cycle: 
tricarboxylic acid cycle. 
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human volunteers or to experimental animals is well suited to investigate the relationship 
between neuronal activity, energy requirements, and glucose metabolism, because several of 
the downstream metabolites of glucose (lactate, alanine, glutamate, glutamine GABA, 
aspartate – see Fig. 1)  can be detected by 13C MRS. 
 
Fig. 1. 13C MR spectrum of a brain extract from a mouse that received 150 µmol [U- 13C] 
glucose intravenously in the awake state and was sacrificed after 5 minutes. Peak numbers: 
1, lactate C3; 2, glutamate C4; 3, GABA C2; 4, glutamine C4, 5, aspartate C3, 6: lactate C2; 7, 
alanine C3, 8: glutamate C3, which is labeled after a full turn of the TCA cycle. *Internal 
standard (dioxane). Note the strong 13C labeling of glutamate C4 and lactate C3 from [U-
13C]glucose. Reprinted from Nguyen et al., 2003, with permission from the publisher. 
Administration of 13C-labeled glucose intravenously (i.v.) or intraperitoneally leads to 
predominant labeling of glutamate in the brain (Figs. 1 and 2). This is so, because glutamate 
is present in concentrations that allow detection by 13C MRS, and because virtually all 
glucose that enters the brain is metabolized through glutamate: glutamate equilibrates with 
α-ketoglutarate of the tricarboxylic acid (TCA) cycle, through which glucose is metabolized 
oxidatively. Briefly, 13C-glucose is metabolized to 13C-acetyl-CoA, which reacts with 
oxaloacetate to form citrate. Acetyl-CoA gives rise to the 1st and 2nd carbons of citrate, which 
correspond to the 5th and 4th carbon positions in α-ketoglutarate and glutamate (Fig. 2). 
Logically, these two positions are the first to be labeled from glucose, provided that uniformly 
labeled glucose, [U-13C]glucose is being used. If [1-13C]glucose is used, which is often the case, 
the 2nd position of acetyl-CoA becomes labeled, and hence the 4th position of glutamate (e.g. 
Fitzpatrick et al., 1990; Shank et al., 1993;  Mason et al., 1999; see Figs. 1 and 2).  
However, when α-ketoglutarate is metabolized further through the TCA cycle, succinate is 
formed. Succinate has four carbon atoms and is symmetrical, so the label is now scrambled 
between the 1st + 2nd positions and the 3rd + 4th positions (or the 2nd and 3rd positions if [1-
13C]glucose is being used). From succinate fumarate, malate, and oxaloacetate are formed 
before another molecule of acetyl-CoA enters the TCA cycle to form citrate. The labeling of 
the 2nd and 3rd positions in succinate, fumarate, malate, and oxaloacetate correspond to the 
2nd and 3rd positions in glutamate. Labeling of these positions in glutamate reflects passage 
of 13C through the TCA cycle (Fig. 1 and 2). From the labeling of the 2nd and 3rd vs. the 4th 
positions in glutamate from [1-13C]glucose an impression of the TCA cycle rate may be 
gained, or the rate may even be calculated (Hassel et al., 1995a; 1997; Mason et al., 1999; 
Hyder et al., 2003). 
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Fig. 2. Simplified scheme of glycolysis and the TCA cycle. Glucose is metabolized 
glycolytically to pyruvate, which may undergo decarboxylation in the pyruvate 
dehydrogenase reaction to become acetyl-CoA. Acetyl-CoA enters the TCA cycle to 
condense with oxaloacetate (OAA) and form citrate. The two carbons from acetyl-CoA that 
contribute to citrate (and hence α-ketoglutarate, glutamate, glutamine and GABA) are 
shown in italics. Due to the symmetry of succinate these two carbons are distributed evenly 
between the C1+C2 positions and the C3+C4 positions in succinate and in fumarate, malate 
and oxaloacetate, which are formed downstream of succinate. Pyruvate may also become 
aminated to alanine or reduced to lactate. 
Oxaloacetate equilibrates with aspartate, and whereas oxaloacetate at a tissue concentration 
of ~10 nmol/g brain tissue (Siesjö, 1978) defies detection by 13C MRS, aspartate is readily 
detected, especially its 2nd and 3rd carbon positions, the labeling of which reflects the passage 
of 13C through the TCA cycle (Figs. 1 and 2). It has been shown with various techniques that 
aspartate is concentrated in GABAergic neurons (Ottersen and Storm-Mathisen, 1985; 
Hassel et al., 1992; 1995b). With 13C MRS this has been verified by blocking the TCA cycle of 
GABAergic neurons specifically; this leads to a marked reduction in the 13C labeling of 
aspartate from [1-13C]glucose (Hassel and Sonnewald, 1995a; Johannessen et al., 2001). 
Inhibition of TCA cycle activity by drugs or toxins may reduce the 13C labeling of glutamate, 
GABA, or glutamine from [13C]glucose (e.g. Hassel and Sonnewald, 1995a). But because 
TCA cycle activity is closely coupled to neuronal activity, any influence that reduces brain 
activity (e.g. anesthetics, antiepileptic drugs) will reduce glucose metabolism in the brain 
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and hence 13C labeling of glucose metabolites. Therefore, a reduction in the labeling of 
cerebral metabolites from [13C]glucose must be interpreted with some caution. Such a 
reduction does not necessarily imply a direct effect, e.g. of a drug, on TCA cycle activity, for 
instance through enzyme inhibition.  
Conversely, any influence that leads to increased activation of the brain may increase 
glucose metabolism and increase 13C labeling from [13C]glucose. Such effects have been seen 
in human subjects and in rats (Hyder et al., 1996; Patel et al., 2004). However, it should be 
noted that although previous studies on a variety of experimentally induced conditions, 
including epileptic seizures and stroke, have shown increased uptake of the glucose 
analogue deoxyglucose by  positron emission tomography (PET) or autoradiographic 
methods, data obtained with 13C MRS seem to indicate that the oxidative metabolism of 
glucose may be only little affected or even reduced (Petroff et al., 2002; Eloqayli et al., 2004; 
Nguyen et al., 2007a; Pan et al., 2008; Håberg et al., 2009). The same is true for other 
conditions that would be expected to entail an increased energy demand, e.g. traumatic 
brain injury (Bartnik et al., 2007; Scafidi et al., 2009). Deoxyglucose is a substrate for the 
glucose transporter in the blood-brain barrier and in neurons, as well as for the first enzyme 
of glucose metabolism, hexokinase, which phopsphorylates glucose and deoxyglucose to 
their 6-phospho- derivatives. But once phophorylated deoxyglucose is not metabolized 
further and accumulates intracellularly; this allows its detection by PET or autoradiography. 
It follows that the deoxyglucose-based methods strictly detect the transport and initial 
phosphorylation of deoxyglucose, whereas 13C MRS detection of glutamate labeling from 
[13C]glucose reflects both glycolytic and oxidative metabolic activity in the brain.  
The possibility of visualizing brain energy metabolism appeared to pave the way for studies 
in which brain activity, including sensory activation and thought processes, could be 
monitored by 13C MRS. It soon became clear, however, that the increase in glucose 
metabolism caused by various forms of physiological activation, was quite small, and not 
always readily detectable on the background of a high basal metabolic rate in the un-
anesthetized brain (Shulman et al., 2004).  
3. Visualization of the metabolic interplay between astrocytes and neurons 
The cellular complexity of the brain makes it difficult to assess the metabolic activity of 
individual cell types separately. However, because some metabolic pathways are unique to 
certain cells, and because some metabolic substrates are metabolized selectively by certain 
cell types, some degree of metabolic dissection of the brain is made possible. First we 
consider the transfer of glutamine from astrocytes to neurons as a precursor for glutamate 
and GABA in neurons. Thereafter we discuss the transfer of glutamate from neurons to 
astrocytes during glutamatergic neurotransmission.  
In the brain, acetate is metabolized oxidatively by astrocytes and not by neurons. Because 
astrocytes express glutamine synthetase (Martinez-Hernandez et al., 1977), isotopically 
labeled acetate (given i.v. or intracerebrally) leads to preferential labeling of glutamine (van 
den Berg et al., 1969; Hassel et al., 1997; Lebon et al., 2002; Deelchand et al., 2009). Glutamine 
is exported from astrocytes to the extracellular fluid, from where it is taken up by neurons, 
both glutamatergic and GABAergic. Inside neurons glutamine becomes deamidated to 
glutamate by phosphate-activated glutaminase (Kvamme et al., 2001), a mitochondrial 
enzyme, which in the brain appears to be expressed only by neurons. In GABAergic neurons 
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the glutamine-derived glutamate becomes decarboxylated to GABA by glutamic acid 
decarboxylase (GAD), an enzyme that in the brain is expressed in inhibitory GABAergic 
neurons (Fonnum et al., 1970). Therefore, when administration of 13C-labeled acetate to 
experimental animals leads to 13C labeling of GABA, this labeling illustrates a series of 
metabolic and transport-related events (Fig. 3) that highlights the role of (astrocytic) 
glutamine as a precursor of (neuronal) glutamate and GABA (Hassel et al., 1997). 
 
Fig. 3. Metabolism of [13C]acetate in astrocytes with formation of [13C]glutamine, which is 
transferred to neurons, where it is deamidated to [13C]glutamate. In GABAergic neurons 
[13C]glutamate is decarboxylated to [13C]GABA. The spectrum is from a brain extract from a 
mouse that received [1,2-13C]acetate, 150 mol i.v. and was sacrificed after 15 minutes. Peaks 
are:  1, alanine C-3; 2, lactate C-3; 3, GABA C-3; 5, glutamine C-3; 6, glutamate C-3; 7, 
glutamine C-4; 8, glutamate C-4;  10, GABA C-2; 11, aspartate C-3; 12, GABA C-4. Note the 
strong labeling of glutamine compared to results with [13C]glucose (Fig. 1) (From Hassel et 
al., 1997, with permission from the publisher). Thus, formation of [13C]GABA from 
[13C]acetate illustrates astrocytic uptake and oxidative metabolism of [13C]acetate, glutamine 
synthetase activity, the activity of glutamine transporters at the astrocytic and neuronal cell 
membranes, neuronal glutaminase activity, and glutamate decarboxylase activity. 
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An enigma of brain metabolism is why acetate is oxidized only by astrocytes and not by 
neurons. Waniewski and Martin (1998) provided evidence that acetate is taken up across the 
cell membrane only in astrocytes. This finding was unexpected, since acetate is a small 
monocarboxylate, for which neurons are richly equipped with transporters (Bergersen, 
2007). Nguyen et al (2007b) later found that neurons take up propionate (which is closely 
related to acetate), which suggested that even acetate is taken up (but not metabolized) by 
neurons. Later it was found that administration of propionate to mice leads to an increase in 
brain GABA levels, suggesting an inhibitory action of propionate on the GABA-degrading 
enzyme GABA transaminase (Hassel et al., unpublished). GABA transaminase is an 
intramitochondrial enzyme in GABAergic neurons (Schousboe et al., 1974), and its inhibition 
by a small monocarboxylate such as propionate suggests that propionate (and acetate) is taken 
up by neurons and neuronal mitochondria, but that the latter are deficient in the enzyme that 
converts acetate and propionate into their mitochondrial CoA derivatives.  
Because glutamate is readily labeled from 13C-labeled precursors, there has been 
considerable interest in identifying transmitter glutamate with 13C MRS. Glutamate is the 
main excitatory neurotransmitter in the central nervous system. While glutamate serves 
many functions in the brain, it has been estimated that 2-20% of the total amount of brain 
glutamate serves a neurotransmitter function (Hassel and Dingledine, 2006). After release 
from synaptic nerve endings glutamate is largely taken up by astrocytes that surround the 
synaptic cleft, and converted into glutamine (Danbolt, 2001). This process may be illustrated 
with 13C MRS. Administration of 13C-labeled glucose to experimental animals leads to rapid 
13C labeling of glutamate and, after a delay, of glutamine. This labeling of glutamine to a 
large extent reflects uptake of (neuronal) transmitter glutamate into astrocytes. This was 
shown in an experiment in which mice had their astrocytic TCA cycle inhibited by the glia-
specific metabolic inhibitor fluoroacetate (Hassel et al., 1997). The mice could not form 
glutamate or glutamine through their TCA cycle activity, but they still produced 13C-
glutamine from 13C-glucose. Formation of glutamine from 13C-glucose was interpreted to 
reflect formation of 13C-glutamate from 13C-glucose in neurons, release of 13C-labeled 
transmitter glutamate from neurons, uptake into astrocytes of the released 13C-labeled 
transmitter glutamate and subsequent amidation by glutamine synthetase (Fig. 4). 
The exchange between neurons and astrocytes of glutamate and glutamine has been the 
subject of many studies, in both human subjects and experimental animals (Shen et al., 1999; 
see Rothman et al., 1999; 2003, for review). Interpretation of 13C MRS after infusion of 13C-
labeled glucose into awake humans indicated that the flux of glutamate from neurons to 
astrocytes was close to 50% of the cerebral metabolism of glucose. This would suggest a 
massive transfer of glutamate from neurons to astrocytes. However, if this is true, it is still 
not known whether all this glutamate is transmitter glutamate in the sense that it originates 
from presynaptic vesicles. 
In 13C MRS studies of the brain, acetate is used as a glial substrate, and glucose is used as an 
energy substrate for all brain cells, but with a dominant contribution from (glutamatergic) 
neurons. As will become evident below ('Identification of alternative substrates for brain 
energy metabolism'), lactate and pyruvate have become regarded as more purely neuronal 
substrates that are used by glutamatergic and GABAergic neurons alike, whereas glycerol 
appears to be a substrate specifically used by GABAergic neurons (Nguyen et al., 2003). 
Thus, some degree of metabolic dissection of the brain is made possible by combining the 
administration of an appropriate 13C-labeled energy substrate with 13C MRS.  
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Fig. 4. Uptake of transmitter glutamate by astrocytes. In this experiment mice received the 
glia-specific metabolic inhibitor fluoroacetate, which blocks the astrocytic TCA cycle at the 
level of aconitase. Thus, the ability of astrocytes to form glutamate and hence glutamine 
from α-ketoglutarate from their own TCA cycle was blocked. Even so, glutamine was 
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formed from [13C]glucose, presumably because 13C-labeled transmitter glutamate was still 
being released from neurons and taken up by astrocytes with subsequent formation of 
[13C]glutamine. The upper spectrum is from the brain of a mouse that received [1,2-
13C]acetate and [1-13C]glucose. The doubly labeled acetate gives rise to the double peaks in 
glutamine C4 (peak 7). The lower spectrum is from a mouse, whose astrocytic TCA ycle was 
blocked by fluoroacetate; here only glutamine labeled from [1-13C]glucose (single peak 7) 
can be seen  (From Hassel et al., 1997, with permission from the publisher). 
4. Identification of alternative substrates for brain energy metabolism 
Serum glucose is considered the physiological energy substrate of the brain. Even so, a 
number of substrates may feed into the glycolytic pathway or the TCA cycle of brain cells. 
For example, lactate, which was shown by 13C MRS to be a substrate for brain metabolism in 
mice (Hassel and Bråthe, 2000), was recently shown by 13C MRS to contribute importantly to 
energy metabolism in the human brain under physiological conditions (Gallagher et al., 
2009; Boumezbeur et al., 2010). The ability of a substrate to function as a metabolic substrate 
for brain cells depends on its ability to cross the blood-brain barrier, i.e. on the presence of 
specific transporter proteins in the barrier. Further, brain cells must have the necessary 
transporters to take the substrates up from the extracellular fluid as well as the enzymes 
necessary for their metabolism. A substrate that is not metabolized in the brain after i.v. 
injection may prove to be metabolized after intracerebral injection, a finding that points to 
transport limitations at the blood-brain barrier; this holds true for dicarboxylates like 
fumarate and malate (Hassel et al., 2002); if injected directly into the brain parenchyma, 
these substrates are taken up into astrocytes and rapidly metabolized through the TCA cycle 
to glutamine, indicating the presence of the plasma membrane dicarboxylate transporter 
predominantly in astrocytes. A similar situation exists for the monosaccharide fructose 
(Hassel et al., submitted), which hardly crosses the blood-brain barrier at all. This can be 
shown by giving mice [13C]fructose i.v.; in contrast to liver, the brain does not accumulate 
the injected [13C]fructose, as can be shown by 13C MRS of brain and liver extracts. However, 
if fructose is injected into the brain parenchyma, it becomes metabolized. The oxidation of 
fructose by brain tissue would explain the ability of fructose to support energy-requiring 
processes, such a axonal activity, in vitro (Meakin et al., 2007). 
Even though a substrate crosses the blood-brain barrier, the enzymatic machinery required 
for its metabolism may not be present in the brain. An example is propionate, which readily 
crosses the blood-brain barrier, but hardly becomes metabolized in the brain (Nguyen et al., 
2007b; Morland et al., in prep). The enzymes required for the initial metabolism of 
propionate, propionyl-CoA synthetase is expressed at low levels, making it difficult to 
detect propionate metabolites by 13C MRS after i.v. administration of [13C]propionate to 
experimental animals. Cerebral metabolism of propionate may be detected with 
radiolabeled propionate, however, owing to the higher sensitivity of radiodetective methods 
(scintillation counting) than of 13C MRS (Nguyen et al., 2007b). 
With the use of 13C MRS -hydroxybutyrate (Künnecke et al., 1993; Pan et al., 2002; Andrews 
et al., 2009), lactate (Hassel and Bråthe, 2000; Tyson et al., 2003; Boumezbeur et al., 2010), 
and pyruvate (Gonzalez et al., 2005) have been shown to be energy substrates for the brain 
after i.v. injection, pointing to the existence of the appropriate monocarboxylate transporters 
at the blood-brain barrier. The predominant labeling of glutamate (over glutamine) points to 
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a predominantly neuronal metabolism of these subtrates (Fig. 5). Even octanoate has been 
shown to be metabolized by the brain (Ebert et al., 2003), suggesting a certain capacity for 
fatty acid metabolism in the brain; the preferential labeling of glutamine pointed to 
astrocytes as the main metabolic compartment. 
 
Fig. 5. 13C MR spectra of brain extracts of mice that received [3-13C]pyruvate or [2-
13C]pyruvate i.v. The (labeling of) individual carbon positions in certain metabolites is 
indicated. Wake mice received 9 mmoles/kg [3-13C]pyruvate (upper panel) or [2-
13C]pyruvate (lower panel) i.v. Survival time was 5 min. [3-13C]Pyruvate labels the C3 of 
lactate (Lac) and alanine (Ala), the C4 of glutamate (Glu) and glutamine (Gln), and GABA 
C2 (but not glutamate C5 or the C1 of GABA or lactate; insert). [2-13C]Pyruvate labels 
lactate and alanine C2, and glutamate C5, GABA C1 and lactate C1 (insert). D is dioxane 
(internal standard). The peak corresponding to Glu C4 in lower spectrum represents 
naturally abundant 13C-glutamate. Reprinted from Gonzalez et al., 2005, with permission 
from the publisher. 
13C-Labeled acetate also yields good labeling of cerebral amino acids, predominantly 
glutamine, after i.v. injection, a finding that points to their metabolism in astrocytes (see 
above, 3. Visualization of the metabolic interplay between astrocytes and neurons). The 
labeling of amino acids in the brain from [13C]acetate is on a level similar to that achieved 
with [13C]glucose (Hassel et al., 1995a;1997), which suggests that acetate could support brain 
energy metabolism; this has been shown in hypoglycemic mice (Urion et al., 1979). 
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An interesting example of the power of 13C MRS in elucidating cell-specific metabolism in 
the CNS is the avid labeling of GABA from [13C]glycerol (Nguyen et al., 2003); this labeling 
greatly exceeded that of glutamate and glutamine (Fig. 6), pointing to GABAergic neurons 
as the predominant cell compartment for glycerol metabolism. A later 13C MRS study 
showed that glycerol is being produced from glucose by both neurons and astrocytes and 
that this production increases during hypoxia or epileptic seizures (Nguyen et al., 2007c). 
The two findings put together (formation of glycerol in both neurons and astrocytes and its 
metabolism by GABAergic neurons) could point to a 'glycerol cycle' in the brain.  
 
Fig. 6. 13C MR spectra of brain extracts from mice that received [U- 13C]glycerol i.v. Wake 
mice received 150 µmol [U-13C]glycerol and were killed at 5 or 15 min. Peak numbers: 1, 
lactate C3; 2, glutamate C4; 3, GABA C2; 4, glycerol C1 + C3. *Internal standard (dioxane). 
Note the strong labeling of GABA C2 relative to glutamate C4 at 15 min after injection of  
[U-13C]glycerol in comparison with the much higher labeling of glutamate from 13C-labeled 
glucose or pyruvate (Figs. 1 and 5). Reprinted from Nguyen et al., 2003, with permission 
from the publisher. 
5. Identification of metabolic pathways from the 
13
C labeling of specific 
carbon positions in glutamate and glutamine 
In the second paragraph of this paper ('13C MRS for the visualization of brain energy 
metabolism') the 13C labeling of glutamate from [13C]glucose through TCA cycle activity is 
described. In fact, any 13C-labeled substrate that gives rise to 13C-labeled acetyl-CoA will 
label glutamate and glutamine in positions that reflect the entry of label into the TCA cycle 
and its subsequent turning in the cycle. This applies to 13C-labeled lactate, pyruvate, alanine, 
beta-hydroxybutyrate, acetate, butyrate, glycerol, and others. However, substrates that give 
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rise to 13C-labeled pyruvate in the brain (glucose, pyruvate, lactate, alanine, glycerol) may 
enter the TCA cycle through two different enzymatic routes. The first, which gives rise to 
acetyl-CoA, is pyruvate dehydrogenase, which removes a carboxylic group from pyruvate 
in the form of CO2. The second route involves the addition of a carboxylic group (from CO2 
or HCO3-) to pyruvate to produce oxaloacetate or its immediate precursor malate (See upper 
part of Fig. 7); these reactions are known as pyruvate carboxylation. In astrocytes, the 
reaction is catalyzed by pyruvate carboxylase, in neurons, it may be catalyzed by malic  
enzyme. These reactions are 'anaplerotic', meaning that they function to 'fill up' the TCA 
cycle with intermediates. They are thought to compensate for the loss of α-ketoglutarate 
inherent in export of glutamine from astrocytes and for the similar loss of α-ketoglutarate 
inherent in glutamatergic and GABAergic neurotransmission when (See below) astrocytes 
take up glutamate or GABA from the synaptic cleft. 
 
Fig. 7. Reversible pyruvate carboxylation and equilibration of malate with fumarate, which 
explains rapid formation of 13CO2 from [1-13C]pyruvate. [1-13C]Pyruvate undergoes 
carboxylation to [1-13C]malate, presumably by malic enzyme. [1-13C]Malate equilibrates with 
the symmetrical fumarate, so that both [1-13C]malate and [4-13C]malate are formed. 
Decarboxylation of these malates produces 13CO2 as well as unlabeled CO2. The 13C is 
represented in italics. 
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When pyruvate is 13C-labeled these reactions lead to the formation of 13C-labeled malate and 
oxaloacetate. Pyruvate labeled in the 3rd carbon (which originates from glucose labeled in 
the 1st position, [1-13C]glucose) leads to formation of malate or oxaloacetate labeled in the 
3rd carbon. This carbon position corresponds to the 2nd carbon in glutamate and 
glutamine. In several studies the greater labeling of the 2nd than the 3rd carbon in 
glutamine has been taken as evidence of pyruvate carboxylase activity in astrocytes 
(Shank et al., 1993; Hassel et al., 1995a; Serres et al., 2008). A similar preferential labeling 
of the 2nd over the 3rd carbon in glutamate has not been consistently found, apparently 
pointing to the absence of pyruvate carboxylation in neurons. However, oxaloacetate and 
malate tend to equilibrate with the symmetrical fumarate, leading to scrambling of label 
between the two carbon position. 13C MRS evidence of such scrambling in neurons has 
been reported in both cultured neurons (Merle et al., 1996) and in vivo (Hassel et al., 2000; 
Gonzalez et al., 2005). Another way to study pyruvate carboxylation is to use glucose 
labeled in the 2nd position. Glucose labeled in this position ([2-13C]glucose) does not label 
acetyl-CoA, but it  may label the 2nd and 3rd positions in glutamate and glutamine through 
pyruvate carboxylation. Mason et al (2007) showed in awake human subjects the flux 
through pyruvate carboxylation to be approximately 6% of that through pyruvate 
dehydrogenase (the activity of which was studied with [1-13C]glucose). This value was in 
good agreement with previous 13C MRS studies in rats (Shank et al., 1993) and with 
previous estimates based on radiolabeling studies (Van den Berg, 1973).  
Formation of pyruvate from TCA cycle intermediates malate or oxaloacetate (through the 
decarboxylating activities of malic enzyme and phosphoenolpyruvate carboxykinase, 
respectively) is termed pyruvate recycling. This process takes place in the brain (Cerdan et 
al., 1990; Hassel and Sonnewald, 1995b; Cruz et al., 1998) as it does in liver. In one study this 
process was identified in brain by 13C MRS of brain extracts from rats that had received 
[13C]acetate, which labeled lactate (Hassel and Sonnewald, 1995b). Such labeling can only 
occur through formation of pyruvate from TCA cycle intermediates. When pyruvate thus 
formed (and labeled) enters the TCA cycle through pyruvate dehydrogenase a distinct 
labeling pattern may be seen in glutamate (Cerdan et al., 1990; Håberg et al., 1998). Valid 
criticism of the interpretation of previous studies has come from Serres et al. (2008) who 
pointed out that hepatic gluconeogenesis with 13C labeling of serum glucose from 
[13C]acetate may influence findings in the brain. However, pyruvate recycling also occurs in 
cultured brain cells (astrocytes), in which hepatic gluconeogenesis is not an issue 
(Sonnewald et al., 1996).  
With the use of 13C MRS Gruetter and colleagues were able to determine the concentration 
and turnover of glycogen in the intact brain (van Heeswijk et al., 2010), and they also 
described the formation of N-acetyl-aspartate, which is present in the brain at high 
concentrations, from [13C]glucose, and they determined the turnover rate of this presumed 
'inert' compound (Choi et al., 2004).  
6. The use of hyperpolarization of 
13
C to increase MRS sensitivity 
A problem with 13C MRS is the low sensitivity of the method. This weakness implies that 
13C-labeled metabolic substrates have to be given in large amounts to achieve detection of 
their metabolites. In contrast, radiolabeling studies are done with minute quantities of 
substrate. In an attempt to improve 13C MRS sensitivity, hyperpolarization of 13C-labeled 
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substrates has been done prior to i.v. injection. The MRS signal may thus be enhanced more 
than 10,000 times (Ardenkjaer-Larsen et al., 2003). In some studies pyruvate, which is 
labeled in the carboxylic position, [1-13C]pyruvate, has been used (Hurd et al., 2010; 
Marjańska et al., 2010; Mayer et al., 2011). The [13C]pyruvate is hyperpolarized immediately 
before i.v. injection. The hyperpolarization is lost within some seconds, however, and the 
detection of metabolism of pyruvate is restricted to 13C-labeled lactate, alanine, and CO2 (see 
Fig. 2). Formation of 13CO2 has been interpreted to reflect pyruvate dehydrogenase activity, 
i.e. the formation of acetyl-CoA, which may enter the TCA cycle to form citrate. But in the 
brain the activity of pyruvate dehydrogenase is quite low (Morland et al., 2007), and 
formation of TCA cycle intermediates and related amino acids takes several minutes 
(Gonzalez et al., 2005),  so a more likely explanation for the formation of 13CO2 within a few 
seconds is reversible pyruvate carboxylation (Fig. 3): [13C]pyruvate is carboxylated  to 
[13C]malate, which equilibrates with (the symmetrical) fumarate, so that 13C is distributed 
evenly between the two carboxylic groups of fumarate. [13C]Fumarate equilibrates with 
malate, which may become decarboxylated to pyruvate and CO2. Some of this CO2 will then 
be 13C-labeled. This series of reactions has been described in the brain with the use of [2-
13C]pyruvate and [3-13C]pyruvate (Gonzalez et al., 2005), and they occur much more rapidly 
than the pyruvate dehydrogenase reaction. Another issue in studies that use hyperpolarized 
substrates is the use of anesthesia, which reduces brain metabolism of 13C-labeled substrates 
markedly (Shank et al., 1993).  
Hyperpolarized [13C]pyruvate may prove useful in the diagnostic workup of malignant 
tumors, including brain tumors, which show a greater tendency to convert [13C]pyruvate 
into [13C]lactate than the normal surrounding tissue. Some recent studies even suggest the 
possibility of monitoring tumor response to therapy from the reduced conversion of 
pyruvate into lactate within a day’s time after irradiation or chemotherapy (Day et al., 2007; 
2011; Park et al., 2011). 
7. References 
Andrews MT, Russeth KP, Drewes LR, Henry PG. (2009) Adaptive mechanisms regulate 
preferred utilization of ketones in the heart and brain of a hibernating mammal 
during arousal from torpor. Am. J. Physiol. Regul. Integr. Comp. Physiol. 296:R383-
393.  
Ardenkjaer-Larsen JH, Fridlund B, Gram A, Hansson G, Hansson L, Lerche MH, Servin R, 
Thaning M, Golman K. (2003) Increase in signal-to-noise ratio of > 10,000 times in 
liquid-state NMR. Proc. Natl. Acad. Sci. U. S. A. 100:10158-10163. 
Attwell D, Laughlin SB. (2001) An energy budget for signaling in the grey matter of the 
brain. J. Cereb. Blood Flow Metab. 21:1133-1145. 
Bartnik BL, Lee SM, Hovda DA, Sutton RL. (2007) The fate of glucose during the period of 
decreased metabolism after fluid percussion injury: a 13C NMR study. J. 
Neurotrauma. 24:1079-1092. 
Bergersen LH. (2007) Is lactate food for neurons? Comparison of monocarboxylate 
transporter subtypes in brain and muscle. Neuroscience 145:11-19.  
Boumezbeur F, Petersen KF, Cline GW, Mason GF, Behar KL, Shulman GI, Rothman DL. 
(2010) The contribution of blood lactate to brain energy metabolism in humans 
www.intechopen.com
 
Magnetic Resonance Spectroscopy 
 
42
measured by dynamic 13C nuclear magnetic resonance spectroscopy. J. Neurosci. 
30:13983-13991. 
Cerdan S, Künnecke B, Seelig J. (1990) Cerebral metabolism of [1,2-13C2]acetate as detected 
by in vivo and in vitro 13C NMR. J. Biol. Chem. 265:12916-12926. 
Choi IY, Gruetter R. (2004) Dynamic or inert metabolism? Turnover of N-acetyl aspartate 
and glutathione from D-[1-13C]glucose in the rat brain in vivo. J. Neurochem. 
91:778-787. 
Cruz F, Scott SR, Barroso I, Santisteban P, Cerdán S. (1998) Ontogeny and cellular 
localization of the pyruvate recycling system in rat brain. J. Neurochem. 70:2613-
2619. 
Danbolt NC. (2001) Glutamate uptake. Prog. Neurobiol. 65:1-105. 
Day SE, Kettunen MI, Gallagher FA, Hu DE, Lerche M, Wolber J, Golman K, Ardenkjaer-
Larsen JH, Brindle KM. (2007) Detecting tumor response to treatment using 
hyperpolarized 13C magnetic resonance imaging and spectroscopy. Nat. Med. 
13:1382-1387.  
Day SE, Kettunen MI, Cherukuri MK, Mitchell JB, Lizak MJ, Morris HD, Matsumoto S, 
Koretsky AP, Brindle KM. (2011) Detecting response of rat C6 glioma tumors to 
radiotherapy using hyperpolarized [1- 13C]pyruvate and 13C magnetic resonance 
spectroscopic imaging. Magn. Reson. Med. 65:557-563. 
Deelchand DK, Shestov AA, Koski DM, Uğurbil K, Henry PG. (2009) Acetate transport and 
utilization in the rat brain. J. Neurochem. 109 Suppl 1:46-54. 
Ebert D, Haller RG, Walton ME. (2003) Energy contribution of octanoate to intact rat brain 
metabolism measured by 13C nuclear magnetic resonance spectroscopy. J. Neurosci. 
23:5928-5935. 
Eloqayli H, Dahl CB, Götestam KG, Unsgård G, Sonnewald U. (2004) Changes of glial-
neuronal interaction and metabolism after a subconvulsive dose of 
pentylenetetrazole. Neurochem. Int. 45:739-745. 
Fitzpatrick SM, Hetherington HP, Behar KL, Shulman RG. (1990) The flux from glucose to 
glutamate in the rat brain in vivo as determined by 1H-observed, 13C-edited NMR 
spectroscopy. J. Cereb. Blood Flow Metab. 10:170-179. 
Fonnum F, Storm-Mathisen J, Walberg F. (1970) Glutamate decarboxylase in inhibitory 
neurons. A study of the enzyme in Purkinje cell axons and boutons in the cat. Brain 
Res. 20:259-275. 
Gallagher CN, Carpenter KL, Grice P, Howe DJ, Mason A, Timofeev I, Menon DK, 
Kirkpatrick PJ, Pickard JD, Sutherland GR, Hutchinson PJ. (2009) The human brain 
utilizes lactate via the tricarboxylic acid cycle: a 13C-labelled microdialysis and 
high-resolution nuclear magnetic resonance study. Brain 132:2839-2849. 
Gonzalez SV, Nguyen NH, Rise F, Hassel B. (2005) Brain metabolism of exogenous 
pyruvate. J. Neurochem. 95:284-293. 
Hassel B, Paulsen RE, Johnsen A, Fonnum F. (1992) Selective inhibition of glial cell 
metabolism in vivo by fluorocitrate. Brain Res. 576:120-124. 
Hassel B, Sonnewald U, Fonnum F. (1995a) Glial-neuronal interactions as studied by 
cerebral metabolism of [2-13C]acetate and [1-13C]glucose: an ex vivo 13C NMR 
spectroscopic study. J. Neurochem. 64:2773-2782. 
www.intechopen.com
13
C Magnetic Resonance Spectroscopy in Neurobiology - Its Use in Monitoring  
Brain Energy Metabolism and in Identifying Novel Metabolic Substrates and Metabolic Pathways 
 
43 
Hassel B, Westergaard N, Schousboe A, Fonnum F. (1995b) Metabolic differences between 
primary cultures of astrocytes and neurons from cerebellum and cerebral cortex. 
Effects of fluorocitrate. Neurochem. Res. 20:413-420. 
Hassel B, Sonnewald U. (1995a) Selective inhibition of the tricarboxylic acid cycle of 
GABAergic neurons with 3-nitropropionic acid in vivo. J. Neurochem. 65:1184-
1191. 
Hassel B, Sonnewald U. (1995b) Glial formation of pyruvate and lactate from TCA cycle 
intermediates: implications for the inactivation of transmitter amino acids? J. 
Neurochem. 65:2227-2234. 
Hassel B, Bachelard H, Jones P, Fonnum F, Sonnewald U. (1997) Trafficking of amino acids 
between neurons and glia in vivo. Effects of inhibition of glial metabolism by 
fluoroacetate. J. Cereb. Blood Flow Metab. 17:1230-1238. 
Hassel B, Bråthe A. (2000) Cerebral metabolism of lactate in vivo: evidence for neuronal 
pyruvate carboxylation. J. Cereb. Blood Flow Metab. 20:327-336. 
Hassel B, Dingledine R. (2006) Glutamate. In GJ Siegel (ed) Basic Neurochemistry. Elsevier, 
pp. 267-290. 
Hurd RE, Yen YF, Mayer D, Chen A, Wilson D, Kohler S, Bok R, Vigneron D, Kurhanewicz 
J, Tropp J, Spielman D, Pfefferbaum A. (2010) Metabolic imaging in the 
anesthetized rat brain using hyperpolarized [1-13C] pyruvate and [1-13C] ethyl 
pyruvate. Magn. Reson. Med. 63:1137-1143. 
Hyder F, Chase JR, Behar KL, Mason GF, Siddeek M, Rothman DL, Shulman RG. (1996) 
Increased tricarboxylic acid cycle flux in rat brain during forepaw stimulation 
detected with 1H[13C]NMR. Proc. Natl. Acad. Sci. U. S. A. 93:7612-7617. 
Hyder F, Brown P, Nixon TW, Behar KL. (2003) Mapping cerebral glutamate 13C turnover 
and oxygen consumption by in vivo NMR. Adv. Exp. Med. Biol. 530:29-39. 
Håberg A, Qu H, Bakken IJ, Sande LM, White LR, Haraldseth O, Unsgård G, Aasly J, 
Sonnewald U. (1998) In vitro and ex vivo 13C-NMR spectroscopy studies of 
pyruvate recycling in brain. Dev. Neurosci. 20:389-398. 
Håberg AK, Qu H, Sonnewald U. (2009) Acute changes in intermediary metabolism in 
cerebellum and contralateral hemisphere following middle cerebral artery 
occlusion in rat. J. Neurochem. 109 Suppl 1:174-181. 
Johannessen CU, Qu H, Sonnewald U, Hassel B, Fonnum F. (2001) Estimation of aspartate 
synthesis in GABAergic neurons in mice by 13 C NMR spectroscopy. Neuroreport 
12:3729-3732. 
Künnecke B, Cerdan S, Seelig J. (1993) Cerebral metabolism of [1,2-13C2]glucose and [U-
13C4]3-hydroxybutyrate in rat brain as detected by 13C NMR spectroscopy. NMR 
Biomed. 6:264-277. 
Kvamme E, Torgner IA, Roberg B. (2001) Kinetics and localization of brain phosphate 
activated glutaminase. J. Neurosci. Res. 66:951-958. 
Lebon V, Petersen KF, Cline GW, Shen J, Mason GF, Dufour S, Behar KL, Shulman GI, 
Rothman DL. (2002) Astroglial contribution to brain energy metabolism in humans 
revealed by 13C nuclear magnetic resonance spectroscopy: elucidation of the 
dominant pathway for neurotransmitter glutamate repletion and measurement of 
astrocytic oxidative metabolism. J. Neurosci. 22:1523-1531. 
www.intechopen.com
 
Magnetic Resonance Spectroscopy 
 
44
Marjańska M, Iltis I, Shestov AA, Deelchand DK, Nelson C, Uğurbil K, Henry PG. (2010) In 
vivo 13C spectroscopy in the rat brain using hyperpolarized [1-13C]pyruvate and [2-
13C]pyruvate. J. Magn. Reson. 206:210-218. 
Martinez-Hernandez A, Bell KP, Norenberg MD. (1977) Glutamine synthetase: glial 
localization in brain. Science 195:1356-1358. 
Mason GF, Pan JW, Chu WJ, Newcomer BR, Zhang Y, Orr R, Hetherington HP. (1999) 
Measurement of the tricarboxylic acid cycle rate in human grey and white matter in 
vivo by 1H-[13C] magnetic resonance spectroscopy at 4.1T. J. Cereb. Blood Flow 
Metab. 19:1179-1188. 
Mason GF, Petersen KF, de Graaf RA, Shulman GI, Rothman DL. (2007) Measurements of 
the anaplerotic rate in the human cerebral cortex using 13C magnetic resonance 
spectroscopy and [1-13C] and [2-13C] glucose. J. Neurochem. 100:73-86. 
Mason GF, Petersen KF, Lebon V, Rothman DL, Shulman GI. (2006) Increased brain 
monocarboxylic acid transport and utilization in type 1 diabetes. Diabetes 55:929-
934. 
Mayer D, Yen YF, Takahashi A, Josan S, Tropp J, Rutt BK, Hurd RE, Spielman DM, 
Pfefferbaum A. (2011) Dynamic and high-resolution metabolic imaging of 
hyperpolarized [1-13C]-pyruvate in the rat brain using a high-performance gradient 
insert. Magn. Reson. Med. 65:1228-1233. 
Merle M, Martin M, Villégier A, Canioni P. (1996) [1-13C]glucose metabolism in brain cells: 
isotopomer analysis of glutamine from cerebellar astrocytes and glutamate from 
granule cells. Dev. Neurosci. 18:460-468. 
Morland C, Henjum S, Iversen EG, Skrede KK, Hassel B. (2007) Evidence for a higher 
glycolytic than oxidative metabolic activity in white matter of rat brain. 
Neurochem. Int. 50:703-709. 
Nguyen NH, Bråthe A, Hassel B. (2003) Neuronal uptake and metabolism of glycerol and 
the neuronal expression of mitochondrial glycerol-3-phosphate dehydrogenase. J. 
Neurochem. 85:831-842. 
Nguyen N, Gonzalez SV, Rise F, Hassel B. (2007a) Cerebral metabolism of glucose and 
pyruvate in soman poisoning. A 13C nuclear magnetic resonance spectroscopic 
study. Neurotoxicology 28:13-18.  
Nguyen NH, Morland C, Gonzalez SV, Rise F, Storm-Mathisen J, Gundersen V, Hassel B. 
(2007b) Propionate increases neuronal histone acetylation, but is metabolized 
oxidatively by glia. Relevance for propionic acidemia. J. Neurochem. 101:806-814. 
Nguyen NH, Gonzalez SV, Hassel B. (2007c) Formation of glycerol from glucose in rat brain 
and cultured brain cells. Augmentation with kainate or ischemia. J. Neurochem. 
101:1694-1700. 
Ottersen OP, Storm-Mathisen J. (1985) Different neuronal localization of aspartate-like and 
glutamate-like immunoreactivities in the hippocampus of rat, guinea-pig and 
Senegalese baboon (Papio papio), with a note on the distribution of gamma-
aminobutyrate. Neuroscience 16:589-606. 
Pan JW, Williamson A, Cavus I, Hetherington HP, Zaveri H, Petroff OA, Spencer DD. (2008) 
Neurometabolism in human epilepsy. Epilepsia. 49 Suppl 3:31-41. 
www.intechopen.com
13
C Magnetic Resonance Spectroscopy in Neurobiology - Its Use in Monitoring  
Brain Energy Metabolism and in Identifying Novel Metabolic Substrates and Metabolic Pathways 
 
45 
Pan JW, de Graaf RA, Petersen KF, Shulman GI, Hetherington HP, Rothman DL. (2002) [2,4-
13C2 ]-beta-Hydroxybutyrate metabolism in human brain. J. Cereb. Blood Flow 
Metab. 22:890-898. 
Park I, Bok R, Ozawa T, Phillips JJ, James CD, Vigneron DB, Ronen SM, Nelson SJ. (2011) 
Detection of early response to temozolomide treatment in brain tumors using 
hyperpolarized 13C MR metabolic imaging. J. Magn. Reson. Imaging 33:1284-1290.  
Patel AB, de Graaf RA, Mason GF, Kanamatsu T, Rothman DL, Shulman RG, Behar KL. 
(2004) Glutamatergic neurotransmission and neuronal glucose oxidation are 
coupled during intense neuronal activation. J. Cereb. Blood Flow Metab. 24:972-
985. 
Petroff OA, Errante LD, Rothman DL, Kim JH, Spencer DD. (2002) Glutamate-glutamine 
cycling in the epileptic human hippocampus. Epilepsia 43:703-710. 
Rodrigues TB, Fonseca CP, Castro MM, Cerdán S, Geraldes CF. (2009) 13C NMR tracers in 
neurochemistry: implications for molecular imaging. Q. J. Nucl. Med. Mol. Imaging 
53:631-645. 
Rothman DL, Sibson NR, Hyder F, Shen J, Behar KL, Shulman RG. (1999) In vivo nuclear 
magnetic resonance spectroscopy studies of the relationship between the 
glutamate-glutamine neurotransmitter cycle and functional neuroenergetics. 
Philos. Trans. R. Soc. Lond. B Biol. Sci. 354:1165-1177.  
Rothman DL, Behar KL, Hyder F, Shulman RG. (2003) In vivo NMR studies of the glutamate 
neurotransmitter flux and neuroenergetics: implications for brain function. Annu. 
Rev. Physiol. 65:401-27. 
Scafidi S, O'Brien J, Hopkins I, Robertson C, Fiskum G, McKenna M. (2009) Delayed cerebral 
oxidative glucose metabolism after traumatic brain injury in young rats. J. 
Neurochem. 109 Suppl 1:189-197. 
Serres S, Bezancon E, Franconi JM, Merle M. (2007) Brain pyruvate recycling and peripheral 
metabolism: an NMR analysis ex vivo of acetate and glucose metabolism in the rat. 
J. Neurochem. 101:1428-1240. 
Serres S, Raffard G, Franconi JM, Merle M. (2008) Close coupling between astrocytic and 
neuronal metabolisms to fulfill anaplerotic and energy needs in the rat brain. J. 
Cereb. Blood Flow Metab. 28:712-724.  
Shank RP, Leo GC, Zielke HR. (1993) Cerebral metabolic compartmentation as revealed by 
nuclear magnetic resonance analysis of D-[1-13C]glucose metabolism. J. 
Neurochem. 61:315-323. 
Shen J, Petersen KF, Behar KL, Brown P, Nixon TW, Mason GF, Petroff OA, Shulman GI, 
Shulman RG, Rothman DL. (1999) Determination of the rate of the 
glutamate/glutamine cycle in the human brain by in vivo 13C NMR. Proc. Natl. 
Acad. Sci. U. S. A. 96:8235-8240. 
Shulman RG, Rothman DL, Behar KL, Hyder F. (2004) Energetic basis of brain activity: 
implications for neuroimaging. Trends Neurosci. 27:489-495. 
Siesjö BK. (1978) Brain Energy Metabolism, New York. 
Sonnewald U, Westergaard N, Jones P, Taylor A, Bachelard HS, Schousboe A. (1996) 
Metabolism of [U-13C5] glutamine in cultured astrocytes studied by NMR 




Magnetic Resonance Spectroscopy 
 
46
Tyson RL, Gallagher C, Sutherland GR. (2003) 13C-Labeled substrates and the cerebral 
metabolic compartmentalization of acetate and lactate. Brain Res. 992:43-52. 
Urion D, Vreman HJ, Weiner MW. (1979) Effect of acetate on hypoglycemic seizures in mice. 
Diabetes 28:1022-1026. 
Van den Berg, C. J. (1973) Metabolic compartmentation in the brain (Balázs R and Cremer JE, 
eds), Macmillan, London, pp. 137–166. 
van Heeswijk RB, Morgenthaler FD, Xin L, Gruetter R. (2010) Quantification of brain 
glycogen concentration and turnover through localized 13C NMR of both the C1 
and C6 resonances. NMR Biomed. 23:270-276. 
Waniewski RA, Martin DL. (1998) Preferential utilization of acetate by astrocytes is 
attributable to transport. J. Neurosci. 18:5225-5233. 
www.intechopen.com
Magnetic Resonance Spectroscopy
Edited by Prof. Dong-Hyun Kim
ISBN 978-953-51-0065-2
Hard cover, 264 pages
Publisher InTech
Published online 02, March, 2012
Published in print edition March, 2012
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
Magnetic Resonance Spectroscopy (MRS) is a unique tool to probe the biochemistry in vivo providing
metabolic information non-invasively. Applications using MRS has been found over a broad spectrum in
investigating the underlying structures of compounds as well as in determining disease states. In this book,
topics of MRS both relevant to the clinic and also those that are beyond the clinical arena are covered. The
book consists of two sections. The first section is entitled 'MRS inside the clinic' and is focused on clinical
applications of MRS while the second section is entitled 'MRS beyond the clinic' and discusses applications of
MRS in other academic fields. Our hope is that through this book, readers can understand the broad
applications that NMR and MRS can offer and also that there are enough references to guide the readers for
further study in this important topic.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Bjørnar Hassel (2012). 13C Magnetic Resonance Spectroscopy in Neurobiology - Its Use in Monitoring Brain
Energy Metabolism and in Identifying Novel Metabolic Substrates and Metabolic Pathways, Magnetic
Resonance Spectroscopy, Prof. Dong-Hyun Kim (Ed.), ISBN: 978-953-51-0065-2, InTech, Available from:
http://www.intechopen.com/books/magnetic-resonance-spectroscopy/13c-magnetic-resonance-spectroscopy-
in-neurobiology-its-use-in-monitoring-brain-energy-metabolism-an
© 2012 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
